Company: BLTE
Filing Date: 2025-01-27
Form Type: 424B7
Source: 0001104659-25-006367
Chunk: 20

Company: BELITE BIO, INC
Filing Date: 2025-01-27
Form: 424B7
Chunk 20
---
380 of ordinary shares of our company represented by ADSs upon its exercise of the warrant with an exercise price of $70.00 per ADS issued to the selling shareholder pursuant an inducement offer letter agreement dated as of November 3, 2024 (the “Letter Agreement”), offered under this prospectus supplement and the accompanying prospectus.

We estimate that we will receive gross proceeds of approximately $45.6 million, based on the exercise price of $70.00 per share, assuming that all the outstanding Warrants held by the selling shareholder are exercised. We cannot predict when or if the Warrants will be exercised. It is possible that the Warrants may expire and may never be exercised.

A copy of the Letter Agreement is attached to as Exhibit 10.1to Form 6-K as filed on November 4, 2024 and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying base prospectus form a part.

#### Lock-up Agreements
We have agreed with the selling shareholder that, for a period of 30 days after the issuance of Selling Shareholder Warrants, not to issue ADSs or ordinary shares for equity fundraising or file registration statements. Notwithstanding the foregoing, this lock-up arrangement shall not apply in respect of an exempt issuance, which include the issuance of (a) ordinary shares or options to employees, officers, directors or consultants of the Company pursuant to any share or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, provided that such ordinary shares or options issued to consultants of the Company are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the 30 day prohibition period, (b) other securities exercisable or exchangeable for or convertible into ordinary shares issued and outstanding on November 3, 2024, provided that such securities have not been amended since November 3, 2024 to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with share splits or combinations) or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of our Company, provided that such securities are issued as “restricted securities